



PHARMA MONTHLY

FEBRUARY 2025

PROGRESSIVE[®]
Your Progress Our Priority...

www.progressiveshares.com | [f](#) [x](#) [in](#) [@progressiveshar](#) | [@](#) Research Analyst

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



Key News for the Month

Company

- Dr. Reddy's unit ties up with Shanghai Henlius Biotech
- Alkem Labs acquires two companies specialising in skin care, medtech to bolster domestic business
- Sanofi launches Rezurock against chronic Graft-versus-host disease in India
- Glenmark, Cosmo get MHRA nod for acne treatment medication
- Biocon betting big on new product launches for growth
- Zydus Lifesciences in pact with Synthon for specialty oncology product in the US
- Glenmark launches generic ophthalmic solution in the US market
- KKR set to buy cancer chain HCG
- Zydus Lifesciences inks licensing pact with Zhuhai for cancer drug
- Aurobindo Pharma to commence supplies to Europe from China plant in April
- Glenmark, FDC recall products in US due to manufacturing issues: USFDA
- USFDA issues 5 observations to Aurobindo Pharma arm's facility in AP
- USFDA inspects Aurobindo Pharma USA Inc.'s warehouse facility in New Jersey
- Cipla receives USFDA nod for Nilotinib Capsules
- Cipla's subsidiary receives 2 observations from the USFDA
- Granules acquires Swiss firm for Rs192cr; forays into CDMO space
- Pfizer Board approves marketing, supply pact with Mylan for two brands
- KKR to buy cancer care hospital chain HCG from CVC for USD400mn
- USFDA pulls up Jagsonpal Pharmaceuticals for manufacturing lapses at API plant
- USFDA issues Form 483 with 3 observations to Gland Pharma's Visakhapatnam unit
- Emcure Pharma gets Form 483 with two observations for API plant from USFDA
- Glenmark launches Epinephrine injection in US
- Biocon launches its GLP-1: Liraglutide in the UK

Industry

- Budget 2025 for healthcare: Big changes in import duty for lifesaving medicines
- Pharma exports expected to double to USD65bn by 2030: Report
- India's Pharma market to expand 2.4x over next 5 years, share in global market to hit 5%: Report
- Govt. extends Schedule M implementation deadline till year-end for small, medium pharma firms

Global

- Novartis secures MHRA authorisation for ribociclib
- FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
- Merck expects oncology king Keytruda to face IRA 'price setting' process starting in 2026
- GSK completes acquisition of IDRx, Inc.

Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Caplin Point	Procainamide Hydrochloride Injection	1g/10mL and 1g/2mL vials	Used to treat certain arrhythmia (abnormal heart rhythm)	Pronestyl (Apothecon Inc.)	USD20mn (annual sales Dec'24)
Lupin	Ipratropium Bromide Nasal Solution (Nasal Spray)	0.03% (21mcg/spray)	Indicated for the symptomatic relief of rhinorrhea	Atrovent (Boehringer Ingelheim Pharmaceuticals, Inc.)	USD22mn (annual sales Dec'24)
Lupin	Bosentan Tablets for Oral Suspension	32mg	Indicated for the treatment of pulmonary arterial hypertension (PAH)	Tracleer (Actelion Pharmaceuticals US, Inc.)	USD11mn (annual sales Dec'24)
Natco Pharma	Bosentan Tablets for Oral Suspension	32mg	Indicated for the treatment of pulmonary arterial hypertension (PAH)	Tracleer (Actelion Pharmaceuticals US, Inc.)	USD11mn (annual sales Sept'24)
Caplin Point	Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution	0.2%/0.5% in 5/10/15mL	Indicated for the reduction of elevated intraocular pressure	Combigan (Abbvie Inc.)	USD242mn (annual sales Dec'24)

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Aarti Drugs Ltd	351	-9.9%	-39.9%	-29.7%
Abbott India Ltd	30470	18.4%	1.7%	6.3%
Advanced Enzyme Technologies Ltd	260	-20.8%	-43.3%	-32.2%
Ajanta Pharma Ltd	2488	-3.3%	-19.4%	19.6%
Alembic Pharmaceuticals Ltd	744	-17.0%	-30.3%	-27.5%
Alkem Laboratories Ltd	4635	-5.8%	-22.7%	-7.1%
Ami Organics Ltd	2170	15.3%	58.9%	92.5%
Anuh Pharma Ltd	154	-19.4%	-25.9%	-26.0%
Apollo Hospitals Enterprise Ltd	6052	-9.8%	-10.6%	-4.8%
Artemis Medicare Services Ltd	234	-19.7%	-12.9%	32.6%
Aster DM Healthcare Ltd	403	-15.1%	-1.8%	-16.9%
AstraZeneca Pharma India	6706	-4.7%	-0.4%	21.5%
Aurobindo Pharma Ltd	1058	-7.0%	-32.4%	2.9%
Alivus Lifesciences Ltd	886	-23.5%	-15.3%	1.0%
Bajaj Healthcare Ltd	605	2.9%	51.2%	69.9%
Biocon Ltd	303	-15.91%	-15.2%	11.7%
Bliss GVS Pharma Ltd	125	-16.0%	-2.4%	0.6%
Caplin Point Laboratories Ltd	1823	-4.0%	-1.36%	25.5%
Cipla Ltd/India	1411	-0.6%	-12.9%	-4.4%
Dishman Carbogen Amics Ltd	199	-8.9%	-1.3%	-20.2%
Divi's Laboratories Ltd	5478	1.4%	8.9%	56.0%
Dr. Reddy's Laboratories Ltd	1118	373.6%	-20.1%	-13.0%
Eris Lifesciences Ltd	1181	2.0%	-11.4%	35.1%
FDC Ltd	382	-17.7%	-28.6%	-14.1%
Fermenta Biotech Ltd	225	-40.2%	-25.5%	28.5%
Fortis Healthcare Ltd	610	5.0%	11.7%	44.9%
Gland Pharma Ltd	1552	4.5%	-16.5%	-13.7%
GSK Pharmaceuticals Ltd	2475	22.2%	-11.7%	14.9%
Glenmark Pharmaceuticals Ltd	1279	-8.7%	-25.1%	40.4%
Global Health Ltd	1150	13.1%	5.8%	-20.2%
Granules India Ltd	462	-10.7%	-34.9%	0.4%
Gufic Biosciences Ltd	329	-18.9%	-19.5%	6.5%
Gujarat Themis Biosyn Ltd	219	-24.4%	-39.4%	-36.9%
HealthCare Global Enterprises Ltd	504	2.2%	30.2%	38.6%
Hester Biosciences Ltd	1500	-28.4%	-37.7%	6.5%
Hikal Ltd	351	3.9%	6.9%	25.3%
Indoco Remedies Ltd	198	-19.9%	-45.6%	-43.5%
Indraprastha Medical Corp. Ltd	358	-14.5%	-9.4%	92.2%
IOI Chemicals and Pharma Ltd	305	-14.9%	-31.1%	-23.4%
IPCA Laboratories Ltd	1353	-2.2%	-3.1%	14.0%
J.B.Chemicals & Pharmaceuticals Ltd	1646	-3.4%	67.2%	105.2%
Jagsonpal Pharmaceuticals Ltd	207	-7.3%	-49.7%	-31.8%
Jubilant Pharmova Sciences Ltd	902	2.6%	-2.6%	62.2%
KMC Speciality Hospitals Ltd	65	-7.5%	-26.1%	-28.5%
KIMS Ltd	521	-12.5%	3.6%	13.7%
Kopran Ltd	169	-8.1%	-44.7%	-31.7%
Kovai Medical Center & Hospital Ltd	5376	1.9%	-1.6%	32.5%
Krsnaa Diagnostics Ltd	710	-10.6%	-1.4%	7.2%
Lal PathLabs Ltd	2310	-13.7%	-31.2%	-0.1%


Source: BSE website; All prices are as on 28th February, 2025

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Laurus Labs Ltd	528	3.4%	15.3%	30.3%
Lincoln Pharmaceuticals Ltd	520	-23.0%	-26.2%	-24.2%
Lupin Ltd	1906	-5.8%	-13.4%	18.0%
Marksans Pharma Ltd	205	-10.1%	-14.7%	34.1%
Max Healthcare Institute Ltd	979	-4.3%	13.0%	15.2%
Medicamen Biotech Ltd	509	14.9%	23.9%	2.1%
Metropolis Healthcare Ltd	1587	-7.1%	-24.3%	-1.5%
Morepen Laboratories Ltd	46	-22.8%	-41.8%	-5.4%
Natco Pharma Ltd	772	-32.8%	-49.9%	-21.5%
Nectar Lifesciences Ltd	26	-24.5%	-35.8%	-29.6%
Neuland Laboratories Ltd	10617	-19.7%	-15.1%	49.5%
NGL Fine-Chem Ltd	1046	-36.0%	-52.6%	-48.5%
Narayana Hrudayalaya Ltd	1444	14.0%	13.3%	5.9%
Novartis India Ltd	802	-10.0%	-27.9%	-16.2%
Nureca Ltd	247	-20.0%	-20.1%	-26.7%
Panacea Biotech Ltd	298	-9.1%	20.3%	96.4%
Pfizer Ltd (India)	4052	-8.4%	-32.0%	-11.3%
Piramal Pharma Ltd	190	-13.2%	3.4%	45.8%
Procter & Gamble Health Ltd	4992	-4.9%	-3.9%	-1.9%
Poly Medicure Ltd	2037	-10.2%	-11.9%	28.6%
RPG Life Sciences Ltd	2088	-6.7%	-3.0%	36.3%
Rainbow Children's Medicare Ltd	1243	-9.6%	0.3%	-13.8%
Sanofi India Ltd	5026	-4.3%	-25.5%	-43.1%
Sastasundar Ventures Ltd	218	-21.1%	-31.4%	-38.4%
Sequent Scientific Ltd	149	-4.4%	-9.6%	12.8%
Shalby Ltd	188	-9.8%	-31.2%	-32.5%
Shilpa Medicare Ltd	610	-11.9%	-20.1%	48.4%
Sigachi Industries Ltd	38	-17.9%	-37.3%	-54.8%
SMS Pharmaceuticals Ltd	191	1.0%	-44.2%	23.9%
Solara Active Pharma Sciences Ltd	472	-6.2%	-32.1%	8.0%
SPARC Ltd	113	-30.6%	-50.9%	-68.0%
Strides Pharma Science Ltd	621	8.5%	-52.4%	-20.3%
Sun Pharmaceutical Industries Ltd	1594	-6.6%	-12.1%	1.3%
Supriya Lifescience Ltd	599	-4.2%	7.5%	75.2%
Suven Life Sciences Ltd	105	-8.7%	-29.1%	3.4%
Suven Pharmaceuticals Ltd	1215	24.5%	14.9%	88.9%
Snycom Formulations (India) Ltd	15	-8.6%	-25.1%	8.3%
Syngene International Ltd	653	-12.2%	-22.8%	-7.8%
Take Solutions Ltd	9	-22.3%	-50.8%	-66.3%
Tarsons Products Ltd	305	-15.0%	-32.5%	-34.8%
Thyrocare Technologies Ltd	688	-9.5%	-21.6%	1.1%
Torrent Pharmaceuticals Ltd	2945	-11.1%	-13.9%	12.9%
Themis Medicare Ltd	157	-30.3%	-40.0%	-34.1%
Unichem Laboratories Ltd	607	-15.2%	5.0%	17.5%
Venus Remedies Ltd	296	6.9%	-15.9%	-13.0%
Vijaya Diagnostic Centre Ltd	916	-1.9%	2.4%	39.5%
Vimta Labs Ltd	865	8.4%	42.5%	72.6%
Windlas Biotech Ltd	761	-15.4%	-9.4%	53.1%
Wockhardt Ltd	1159	-9.2%	10.2%	98.9%
Zydus Lifesciences Ltd	876	-3.7%	-23.0%	-6.1%

Source: BSE website; All prices are as on 28th February, 2025

NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rs mn)	Change		
			1 M	6 M	12 M
Abbott India Ltd	30470	647475	18.4%	1.7%	6.3%
Alkem Laboratories Ltd	4635	554172	-5.8%	-22.7%	-7.1%
Aurobindo Pharma Ltd	1058	614459	-7.0%	-32.4%	2.9%
Ajanta Pharma Ltd	2488	310719	-3.3%	-19.4%	19.6%
Biocon Ltd	303	363302	-15.9%	-15.2%	11.7%
Cipla Ltd	1411	1139503	-0.6%	-12.9%	-4.4%
Divi's Laboratories Ltd	5478	1454104	1.4%	8.9%	56.0%
Dr. Reddy's Laboratories Ltd	1118	1234014	373.6%	-20.1%	-13.0%
Gland Pharma Ltd	1552	255761	4.5%	-16.5%	-13.7%
Glenmark Pharmaceuticals Ltd	1279	360848	-8.7%	-25.1%	40.4%
Granules India Ltd	462	111923	-10.7%	-34.9%	0.4%
Ipca Laboratories Ltd	1353	343376	-2.2%	-3.1%	14.0%
J.B. Chemicals & Pharmaceuticals Ltd	1646	256049	-3.4%	67.2%	105.2%
Laurus Labs Ltd	528	284644	3.4%	15.3%	30.3%
Lupin Ltd	1906	869674	-5.8%	-13.4%	18.0%
Mankind Pharma Ltd	2290	944799	-6.9%	-5.7%	11.6%
Natco Pharma Ltd	772	138210	-32.8%	-49.9%	-21.5%
Sun Pharmaceutical Industries Ltd	1594	3824300	-6.6%	-12.1%	1.3%
Torrent Pharmaceuticals Ltd	2945	996823	-11.1%	-13.9%	12.9%
Zydus Lifesciences Ltd	876	881662	-3.7%	-23.0%	-6.1%

Source: NSE website, Company Research; All prices are as on 28th February, 2025



Source: NSE website

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Neha Oza,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com